MBX Biosciences (NASDAQ:MBX) Trading Down 6.3% - Should You Sell?

Key Points

• Shares fell 6.3% to about $31.28 in mid-day trading with only ~62,794 shares changing hands—roughly 89% below the stock's average daily volume.
• Analysts maintain a consensus rating of "Moderate Buy" with a consensus price target of $53.25, though individual ratings are mixed (1 Strong Buy, 9 Buy, 2 Sell).
• Insider buying: CEO P. Kent Hawryluk purchased 18,500 shares at $28.41 on March 13, increasing his holdings to 486,777 shares, and insiders now own 52.19% of the stock.

Shares of MBX Biosciences, Inc. (NASDAQ:MBX - Get Free Report) dropped 6.3% during mid-day trading on Friday . The stock traded as low as $31.32 and last traded at $31.28. Approximately 62,794 shares changed hands during trading, a decline of 89% from the average daily volume of 591,346 shares. The stock had previously closed at $33.39.

Analysts Set New Price Targets

Several research analysts have recently commented on MBX shares. Truist Financial set a $50.00 target price on MBX Biosciences in a report on Monday, March 9th. Wall Street Zen downgraded MBX Biosciences from a "hold" rating to a "sell" rating in a report on Saturday, April 11th. Lifesci Capital raised MBX Biosciences to a "strong-buy" rating in a report on Tuesday, March 31st. TD Cowen reissued a "buy" rating on shares of MBX Biosciences in a report on Thursday, March 12th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of MBX Biosciences in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $53.25.

MBX Biosciences Price Performance

The firm has a market capitalization of $1.52 billion, a P/E ratio of -13.25 and a beta of 1.25. The stock's 50 day moving average is $32.04 and its two-hundred day moving average is $29.91.

MBX Biosciences (NASDAQ:MBX - Get Free Report) last posted its quarterly earnings results on Thursday, March 12th. The company reported ($0.49) earnings per share for the quarter, topping analysts' consensus estimates of ($0.64) by $0.15. As a group, equities research analysts expect that MBX Biosciences, Inc. will post -2.9 EPS for the current year.

Insider Buying and Selling at MBX Biosciences

In other MBX Biosciences news, CEO P. Kent Hawryluk purchased 18,500 shares of the company's stock in a transaction that occurred on Friday, March 13th. The stock was acquired at an average cost of $28.41 per share, with a total value of $525,585.00. Following the completion of the purchase, the chief executive officer directly owned 486,777 shares in the company, valued at approximately $13,829,334.57. This represents a 3.95% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 52.19% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On MBX Biosciences

Large investors have recently bought and sold shares of the company. GF Fund Management CO. LTD. bought a new stake in MBX Biosciences in the fourth quarter valued at approximately $28,000. Russell Investments Group Ltd. increased its stake in MBX Biosciences by 4,131.4% in the third quarter. Russell Investments Group Ltd. now owns 1,481 shares of the company's stock valued at $26,000 after purchasing an additional 1,446 shares in the last quarter. Royal Bank of Canada increased its stake in MBX Biosciences by 59.6% in the fourth quarter. Royal Bank of Canada now owns 1,532 shares of the company's stock valued at $49,000 after purchasing an additional 572 shares in the last quarter. FNY Investment Advisers LLC acquired a new position in shares of MBX Biosciences in the third quarter valued at approximately $27,000. Finally, California State Teachers Retirement System boosted its holdings in shares of MBX Biosciences by 64.7% in the fourth quarter. California State Teachers Retirement System now owns 1,754 shares of the company's stock valued at $55,000 after buying an additional 689 shares during the period.

MBX Biosciences Company Profile

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.